These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29315762)

  • 1. Effect of apoptosis-associated speck-like protein containing a caspase recruitment domain on vaccine efficacy: Overcoming the effects of its deficiency with aluminum hydroxide adjuvant.
    Lee DK; Lee EY; Kim RH; Kwak HW; Kim JY; Kim H; Kang KW; Lee SM; Park JH; Chang J; Nam JH
    Microbiol Immunol; 2018 Mar; 62(3):176-186. PubMed ID: 29315762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of Aluminum Hydroxide and Monophosphoryl Lipid A Adjuvants in Overcoming CD4+ T Cell Deficiency To Induce Isotype-Switched IgG Antibody Responses and Protection by T-Dependent Influenza Vaccine.
    Ko EJ; Lee YT; Kim KH; Lee Y; Jung YJ; Kim MC; Lee YN; Kang T; Kang SM
    J Immunol; 2017 Jan; 198(1):279-291. PubMed ID: 27881702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection.
    Bungener L; Geeraedts F; Ter Veer W; Medema J; Wilschut J; Huckriede A
    Vaccine; 2008 May; 26(19):2350-9. PubMed ID: 18400340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.
    Ellebedy AH; Lupfer C; Ghoneim HE; DeBeauchamp J; Kanneganti TD; Webby RJ
    Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2927-32. PubMed ID: 21270336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of adjuvant efficacy of chitosan and aluminum hydroxide for intraperitoneally administered inactivated influenza H5N1 vaccine.
    Chang H; Li X; Teng Y; Liang Y; Peng B; Fang F; Chen Z
    DNA Cell Biol; 2010 Sep; 29(9):563-8. PubMed ID: 20380570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.
    Ko EJ; Lee YT; Kim KH; Jung YJ; Lee Y; Denning TL; Kang SM
    J Virol; 2016 Aug; 90(15):6976-6988. PubMed ID: 27226368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.
    Shokouhi H; Farahmand B; Ghaemi A; Mazaheri V; Fotouhi F
    Virus Res; 2018 Jun; 251():40-46. PubMed ID: 29730305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
    Fotouhi F; Shaffifar M; Farahmand B; Shirian S; Saeidi M; Tabarraei A; Gorji A; Ghaemi A
    Arch Virol; 2017 May; 162(5):1251-1260. PubMed ID: 28120096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the immune responses to the CIA06-adjuvanted human papillomavirus L1 VLP vaccine with those against the licensed HPV vaccine Cervarix™ in mice.
    Han JE; Wui SR; Park SA; Lee NG; Kim KS; Cho YJ; Kim HJ; Kim HJ
    Vaccine; 2012 Jun; 30(28):4127-34. PubMed ID: 22561312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.
    van de Sandt CE; Kreijtz JH; Geelhoed-Mieras MM; Vogelzang-van Trierum SE; Nieuwkoop NJ; van de Vijver DA; Fouchier RA; Osterhaus AD; Morein B; Rimmelzwaan GF
    Vaccine; 2014 Sep; 32(43):5614-23. PubMed ID: 25140929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Poly-γ-Glutamic Acid Complexed With Alum Induces Cross-Protective Immunity of Pandemic H1N1 Vaccine.
    Nguyen QT; Kwak C; Lee WS; Kim J; Jeong J; Sung MH; Yang J; Poo H
    Front Immunol; 2019; 10():1604. PubMed ID: 31354739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral influenza-specific immune response upon vaccination in patients with common variable immunodeficiency and unclassified antibody deficiency.
    Hanitsch LG; Löbel M; Mieves JF; Bauer S; Babel N; Schweiger B; Wittke K; Grabowski P; Volk HD; Scheibenbogen C
    Vaccine; 2016 May; 34(21):2417-2423. PubMed ID: 27055021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nasal alum-adjuvanted vaccine promotes IL-33 release from alveolar epithelial cells that elicits IgA production via type 2 immune responses.
    Sasaki E; Asanuma H; Momose H; Furuhata K; Mizukami T; Hamaguchi I
    PLoS Pathog; 2021 Aug; 17(8):e1009890. PubMed ID: 34460865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The avian influenza vaccine Emerflu. Why did it fail?
    Young BE; Sadarangani SP; Leo YS
    Expert Rev Vaccines; 2015; 14(8):1125-34. PubMed ID: 26098721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD47 Plays a Role as a Negative Regulator in Inducing Protective Immune Responses to Vaccination against Influenza Virus.
    Lee YT; Ko EJ; Lee Y; Lee YN; Bian Z; Liu Y; Kang SM
    J Virol; 2016 Aug; 90(15):6746-6758. PubMed ID: 27194758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.